CompletedNCT00191659
Atomoxetine compared with usual care for quality of life in young people with ADHD
About this title
Read the official source — NCT00191659This study evaluated the effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Medication studyAges 7–15United Kingdom
Understand this study
What did researchers investigate?
This study evaluated the effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 7 years to 15 years. Other eligibility criteria applied.
- Listed locations
- BasingstokeSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJune 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 200
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United Kingdom
- Age range
- From 7 Years to 15 Years
- Official registry ID
- NCT00191659
- Official title
Show the full official title
A Randomised, Controlled, Open-Label Study of the Broader Efficacy of Atomoxetine Hydrochloride in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children and Adolescents
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Basingstoke
Interested in joining this study?
Questions about this study
What did researchers investigate?
This study evaluated the effectiveness of Atomoxetine Hydrochloride for people with ADHD.
Who is behind this study?
The study sponsor is Eli Lilly and Company.
Did this study involve medication?
Yes. The study involved medication, including Atomoxetine Hydrochloride.
Who was this study for?
This study was for people with ADHD. Listed age limits: 7 years to 15 years. Other eligibility criteria applied.
Want to explore more studies?
Explore studiesRelated studies
Atomoxetine or placebo to maintain response in adult ADHD
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate Efficacy and Safety of Prolonged Release (PR) OROS® methylphenidate (54 and 72 mg/day) i...